WO2001026623A3 - Treatment of fatigue, head injury and stroke - Google Patents

Treatment of fatigue, head injury and stroke Download PDF

Info

Publication number
WO2001026623A3
WO2001026623A3 PCT/GB2000/003926 GB0003926W WO0126623A3 WO 2001026623 A3 WO2001026623 A3 WO 2001026623A3 GB 0003926 W GB0003926 W GB 0003926W WO 0126623 A3 WO0126623 A3 WO 0126623A3
Authority
WO
WIPO (PCT)
Prior art keywords
noradrenaline
inhibitor
treatment
stroke
fatigue
Prior art date
Application number
PCT/GB2000/003926
Other languages
French (fr)
Other versions
WO2001026623A2 (en
Inventor
David F Horrobin
Cari Loder
Original Assignee
Laxdale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE60042598T priority Critical patent/DE60042598D1/en
Application filed by Laxdale Ltd filed Critical Laxdale Ltd
Priority to MXPA02003724A priority patent/MXPA02003724A/en
Priority to CA2388377A priority patent/CA2388377C/en
Priority to EP00969670A priority patent/EP1220689B1/en
Priority to AU79328/00A priority patent/AU782656B2/en
Priority to PL00354975A priority patent/PL354975A1/en
Priority to HU0203470A priority patent/HUP0203470A3/en
Priority to NZ518306A priority patent/NZ518306A/en
Priority to SK467-2002A priority patent/SK4672002A3/en
Publication of WO2001026623A2 publication Critical patent/WO2001026623A2/en
Publication of WO2001026623A3 publication Critical patent/WO2001026623A3/en
Priority to HR20020309A priority patent/HRP20020309A2/en
Priority to NO20021716A priority patent/NO20021716L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Finger-Pressure Massage (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of treatment of disorders of neurological origin and drug formulations for use in the method are disclosed. These conditions comprise fatigue and associated syndromes of pain, weakness and depressed mood which are associated with chronic fatigue syndrome, brain injury and stroke, stress, fibromyalgia, and irritable bowel syndrome. The treatment comprises administering to a patient in need thereof a selective inhibitor of noradrenaline reuptake combined with either phenylalanine or tyrosine in the same dosage form or the same pack. The noradrenergic drug may be selected from lofepramine, desipramine or reboxetine. The selective inhibitor may be a combined inhibitor of both noradrenaline and serotonin reuptake such as venlafaxine, duloxetine or milnacipran, or an inhibitor of both noradrenaline and dopamine reuptake such as bupropion.
PCT/GB2000/003926 1999-10-12 2000-10-12 Treatment of fatigue, head injury and stroke WO2001026623A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
PL00354975A PL354975A1 (en) 1999-10-12 2000-10-12 Treatment of fatigue, head injury and stroke
MXPA02003724A MXPA02003724A (en) 1999-10-12 2000-10-12 Treatment of fatigue, head injury and stroke.
CA2388377A CA2388377C (en) 1999-10-12 2000-10-12 Medication for the treatment of chronic fatigue syndrome and related symptoms
EP00969670A EP1220689B1 (en) 1999-10-12 2000-10-12 Medicament for the treatment of chronic fatigue syndrome associated with fibromyalgia and irritable bowel syndrome.
AU79328/00A AU782656B2 (en) 1999-10-12 2000-10-12 Treatment of fatigue, head injury and stroke
DE60042598T DE60042598D1 (en) 1999-10-12 2000-10-12 MEDICAMENTS FOR TREATING THE SYNDROME OF CHRONIC TREATMENT ASSOCIATED WITH FIBROMYALGIA AND IRRITANT.
HU0203470A HUP0203470A3 (en) 1999-10-12 2000-10-12 Treatment of fatigue, head injury and stroke
NZ518306A NZ518306A (en) 1999-10-12 2000-10-12 Use of a selective inhibitor of noradrenaline reuptake combined with phenylalanine or tyrosine to treat various diseases
SK467-2002A SK4672002A3 (en) 1999-10-12 2000-10-12 Application of compositions combination for the treatment of fatigue, head injury and stroke
HR20020309A HRP20020309A2 (en) 1999-10-12 2002-04-10 Treatment of fatigue, head injury and stroke
NO20021716A NO20021716L (en) 1999-10-12 2002-04-11 Treatment of fatigue, head injury and stroke

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9924172.1 1999-10-12
GB9924172A GB2355191A (en) 1999-10-12 1999-10-12 Combination formulations for fatigue, head injury and strokes

Publications (2)

Publication Number Publication Date
WO2001026623A2 WO2001026623A2 (en) 2001-04-19
WO2001026623A3 true WO2001026623A3 (en) 2001-06-21

Family

ID=10862624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003926 WO2001026623A2 (en) 1999-10-12 2000-10-12 Treatment of fatigue, head injury and stroke

Country Status (15)

Country Link
US (1) US6441038B1 (en)
EP (1) EP1220689B1 (en)
AU (1) AU782656B2 (en)
CA (1) CA2388377C (en)
CZ (1) CZ20021197A3 (en)
DE (1) DE60042598D1 (en)
GB (1) GB2355191A (en)
HR (1) HRP20020309A2 (en)
HU (1) HUP0203470A3 (en)
MX (1) MXPA02003724A (en)
NO (1) NO20021716L (en)
NZ (1) NZ518306A (en)
PL (1) PL354975A1 (en)
SK (1) SK4672002A3 (en)
WO (1) WO2001026623A2 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1660109A (en) 1999-07-01 2005-08-31 法玛西雅厄普约翰美国公司 Highly selective norepinephrine reuptake inhibitors and methods of using the same
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
CA2475763A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
US20030176773A1 (en) * 2002-03-12 2003-09-18 Gendreau Roger Michael Methods of assessing the level of a subjective symptom
EP1485078B1 (en) * 2002-03-15 2012-09-26 Cypress Bioscience, Inc. Milnacipran for the treatment of irritable bowel syndrome
MXPA04011529A (en) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevention and treatment of functional somatic disorders, including stress-related disorders.
JP4545584B2 (en) * 2002-05-17 2010-09-15 デューク ユニバーシティ Methods for treating obesity
TW200402289A (en) * 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
EP1528920B1 (en) * 2002-08-12 2013-07-24 Yuuichi Murayama Suppression of abnormal proliferation of prion proteins with leucine, isoleucine or valine
EP1558231A4 (en) * 2002-10-03 2010-09-08 Cypress Bioscience Inc Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004045606A1 (en) * 2002-11-19 2004-06-03 Eli Lilly And Company Treatment of gastrointestinal disorders with duloxetine
JP2006516976A (en) * 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド How to treat functional bowel disorders
ATE359079T1 (en) * 2003-01-13 2007-05-15 Dynogen Pharmaceuticals Inc METHOD FOR TREATING NAUSEA, VOMITING, REGAGING, OR ANY COMBINATION THEREOF
FR2851163B1 (en) 2003-02-14 2007-04-27 USE OF DEXTROGYAN ENANTIOMER OF MILNACIPRAN FOR THE PREPARATION OF A MEDICINAL PRODUCT
NZ541733A (en) 2003-02-14 2009-03-31 Pf Medicament Use of the enantiomer (1S,2R) of milnacipran for the preparation of a medicament
CA2519379A1 (en) 2003-04-04 2004-10-21 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
PT2316456T (en) * 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0313630D0 (en) * 2003-06-12 2003-07-16 Wwk Trust The Compositions for the enhanced treatment of depression
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
PT1708690T (en) 2003-11-17 2016-09-19 Biomarin Pharm Inc Treatment of phenylketonuria with bh4
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
BRPI0506829A (en) 2004-01-13 2007-05-29 Univ Duke Anticonvulsant and antipsychotic drug compositions and methods for their use to affect weight loss
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
JP2008509142A (en) * 2004-08-03 2008-03-27 オレキシジェン・セラピューティクス・インコーポレーテッド Combination of bupropion and a second compound to affect weight loss
JP2008514689A (en) * 2004-10-01 2008-05-08 ニューロキュア リミテッド Use of lofepramine pharmaceutical composition for the treatment of ADHD, CFS, FM and depression
EP2436379A1 (en) 2004-11-17 2012-04-04 BioMarin Pharmaceutical Inc. Stable tablet formulation
JP2008523090A (en) * 2004-12-08 2008-07-03 バイオマリン ファーマシューティカル インコーポレイテッド Methods and compositions for the treatment of neonatal pulmonary hypertension
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
DK2135603T3 (en) 2005-11-22 2013-03-25 Orexigen Therapeutics Inc Compositions and Methods for Increasing Insulin Sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
JP2009517393A (en) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド How to treat anxiety
JP2009518415A (en) * 2005-12-05 2009-05-07 バイオマリン ファーマシューティカル インコーポレイテッド Methods and compositions for treatment of disease
WO2007088473A2 (en) * 2006-02-03 2007-08-09 Neurocure Ltd Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
MX2009002715A (en) 2006-09-12 2009-08-12 Adolor Corp Methods for enhancing cognitive function.
WO2008042773A2 (en) * 2006-09-29 2008-04-10 Pdxrx, Inc. Unitary pharmaceutical composition, method, and kit for the treatment or prevention of metabolic or endocrine disorders
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
CN101588795A (en) 2006-11-09 2009-11-25 奥雷西根治疗公司 Wo2008055686
WO2008089148A1 (en) * 2007-01-12 2008-07-24 Biomarin Pharmaceutical Inc. Method of treating a metabolic or neuropsychiatry disorder with a bh4 derivative prodrug
DK3461503T3 (en) 2007-04-11 2022-02-14 Biomarin Pharm Inc METHODS FOR THE ADMINISTRATION OF TETRAHYDROBIOPTERIN, ASSOCIATED COMPOSITIONS AND MEASUREMENT PROCEDURES
EP2357183B1 (en) 2007-05-01 2015-07-01 Concert Pharmaceuticals Inc. Morphinan compounds
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
PL2397158T3 (en) * 2008-10-30 2016-09-30 Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect
JP2013510176A (en) 2009-11-06 2013-03-21 ピエール ファーブル メディカモン Novel crystalline form of (1S, 2R) -2- (aminomethyl) -N, N-diethyl-1-phenylcyclopropanecarboxamide
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
US20120289744A1 (en) 2010-11-03 2012-11-15 Arch Pharmalabs Limited Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts
CA2840363A1 (en) * 2011-06-24 2012-12-27 K-Pax Pharmaceuticals, Inc. Compositions comprising a central nervous system stimulant and select micronutrients useful in the treatment of chronic fatigue
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
RU2493839C1 (en) * 2012-02-28 2013-09-27 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Method of treating chronic fatigue syndrome
EP2858640B1 (en) 2012-06-06 2020-03-25 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
WO2020160263A1 (en) * 2019-01-30 2020-08-06 Synlev Pharmaceuticals Corporation Formulations and methods for treatment of fibromyalgia and related myofascial pain disorders
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988004173A1 (en) * 1986-12-05 1988-06-16 Serotonin Industries Of Charleston Method and composition for treating obesity, depression, drug abuse, and narcolepsy
WO1996011009A1 (en) * 1994-10-05 1996-04-18 Cari Loder Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound
WO1998001157A1 (en) * 1996-07-05 1998-01-15 The Wwk Trust Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter
WO1998008520A1 (en) * 1996-08-29 1998-03-05 Worsley, Andrew, Peter Treatment of pain
WO1998009623A2 (en) * 1996-09-03 1998-03-12 Scotia Holdings Plc Use of cholinergic drugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431670A (en) * 1980-12-19 1984-02-14 Bernardo Heller D-Phenylalanine treatment
GB2297868B (en) 1995-02-07 1999-04-28 Nokia Mobile Phones Ltd A shielding device
JP3128609B2 (en) 1996-02-01 2001-01-29 株式会社小糸製作所 Illumination direction control device for vehicle lighting
US5765240A (en) * 1996-07-31 1998-06-16 L&P Property Management Co. Spring bedding product collapsible in the transverse direction, and method of making it

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988004173A1 (en) * 1986-12-05 1988-06-16 Serotonin Industries Of Charleston Method and composition for treating obesity, depression, drug abuse, and narcolepsy
WO1996011009A1 (en) * 1994-10-05 1996-04-18 Cari Loder Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound
WO1998001157A1 (en) * 1996-07-05 1998-01-15 The Wwk Trust Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter
WO1998008520A1 (en) * 1996-08-29 1998-03-05 Worsley, Andrew, Peter Treatment of pain
WO1998009623A2 (en) * 1996-09-03 1998-03-12 Scotia Holdings Plc Use of cholinergic drugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A.P.WORSLEY, J.ALLAWI: "A combined treatment for severe diabetic neuropathy symptoms", DIABETIC MEDICINE, vol. 15, no. 9, 1998, pages 797, XP000990770 *

Also Published As

Publication number Publication date
PL354975A1 (en) 2004-03-22
HUP0203470A2 (en) 2003-02-28
CA2388377A1 (en) 2001-04-19
SK4672002A3 (en) 2002-09-10
HUP0203470A3 (en) 2005-10-28
GB2355191A (en) 2001-04-18
NO20021716L (en) 2002-06-10
NZ518306A (en) 2004-04-30
AU7932800A (en) 2001-04-23
WO2001026623A2 (en) 2001-04-19
DE60042598D1 (en) 2009-09-03
GB9924172D0 (en) 1999-12-15
AU782656B2 (en) 2005-08-18
CA2388377C (en) 2011-02-01
EP1220689B1 (en) 2009-07-22
US6441038B1 (en) 2002-08-27
HRP20020309A2 (en) 2004-02-29
MXPA02003724A (en) 2003-10-14
EP1220689A2 (en) 2002-07-10
NO20021716D0 (en) 2002-04-11
CZ20021197A3 (en) 2002-09-11

Similar Documents

Publication Publication Date Title
WO2001026623A3 (en) Treatment of fatigue, head injury and stroke
EP2251007A3 (en) Sphingosine-1-phosphate (S1P) receptor agonists for use in the treatment of demyelinating diseases
WO2004047830A3 (en) Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor and the use of said composition for treating bladder dysfunction
HUP0201623A2 (en) Use of (s,s)reboxetine a selective norepinephrine reuptake inhibitor for the preparation of pharmaceutical compositions treating disorders of the nervous system
EP1759701A3 (en) Buproprion Metabolites and Methods of Their Synthesis and Use.
EE200100441A (en) Monoamine reuptake inhibitors for the treatment of central nervous system disorders
EP1712239A3 (en) Interleukin-1 inhibitors in the treatment of diseases
WO2001062341A3 (en) Combination product for the treatment of obesity
WO2004010932A3 (en) Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
WO2002047712A3 (en) Peptide yy and peptide yy agonists for treatment of metabolic disorders
AR026610A1 (en) A PIRROLIDINACETAMIDE DERIVATIVE ONLY OR IN COMBINATION FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
AU2604301A (en) Tnf inhibitors for the treatment of neurological, retinal and muscular disorders
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
WO2000032178A3 (en) Use of siburamine for the treatment of disorders of the central nervous system secondary to organic impairments
WO2003014309A3 (en) Interleukin-1 receptors in the treatment of diseases
NO20054913L (en) Use of clustein for the treatment and / or prevention of peripheral neurological disorders
EP1889614A3 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
WO2005014041A3 (en) Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
EP0824917A3 (en) Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis
WO2007006732A8 (en) Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
WO2004103283A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
EP1723957A3 (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
WO2002039879A3 (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
WO2004100939B1 (en) Combination of the analeptic modafinil and an antidepressant for the treatment of depression
EE200100689A (en) Use of IL6RIL6 Chimera for the preparation of a medicament for the treatment of neurological diseases, and pharmaceutical composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 4672002

Country of ref document: SK

Ref document number: PV2002-1197

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: P20020309A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 518306

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/003724

Country of ref document: MX

Ref document number: 2388377

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 79328/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000969670

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000969670

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-1197

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 518306

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 518306

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 79328/00

Country of ref document: AU